source
- Celldex halts eczema development of barzolvolimab after Phase 2 miss, eyes chronic hives filingCelldex Therapeutics announced it will stop developing its lead antibody barzolvolimab for eczema after the Phase 2 trial did not meet its internal efficacy threshold. The company said it will sti…
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…